about
Characterization of clonogenic multiple myeloma cellsClonogenic multiple myeloma progenitors, stem cell properties, and drug resistanceCancer stem cells: relevance to clinical transplantationCyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastomaTelomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanismsSelf-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors.Relationships between folate and inflammatory features of asthmaPrognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinomaHigh-dose cyclophosphamide for severe aplastic anemia: long-term follow-upGli1 regulates the proliferation and differentiation of HSCs and myeloid progenitors.High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.Targeting Hedgehog--a cancer stem cell pathwayGranulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer.Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheresDNER, an epigenetically modulated gene, regulates glioblastoma-derived neurosphere cell differentiation and tumor propagation.Tumor-initiating cells are rare in many human tumorsSalvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeA direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma.Isolation of stem cells from human pancreatic cancer xenograftsThe redox-sensitive transcription factor Nrf2 regulates murine hematopoietic stem cell survival independently of ROS levels.Cancer Stem Cells: From Bench to BedsideA DNA hypermethylation module for the stem/progenitor cell signature of cancer.Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasBruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaThe multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.Induction of acute lymphocytic leukemia differentiation by maintenance therapyCancer stem cells in multiple myeloma.GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation.Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.
P50
Q24610291-8EFB125D-1E03-4BED-A2BB-1094B18A55F3Q24644883-9D0D98A8-B0E2-4425-AABD-B1BC61C6F05CQ27008959-7037FFDB-263F-438B-B967-3A89C1A58419Q28236409-3D6FF698-1F3C-40D0-A640-90923E7A3D38Q28292633-5069468F-CFAD-427C-82FA-3DA9CAD82326Q28743931-46C9593D-81E2-4E99-93E3-40A2DC6E7200Q33252671-48403C92-98F4-40D3-B7CE-505A241F3481Q33594485-17651A47-A9B2-438A-8E28-BC26059ABC05Q33698761-5F60722D-88B9-472E-85DA-02EACEA6E5EEQ33747331-A66C3870-10D4-4F31-B7B8-A31132FD0C48Q33754614-1E0C7C87-4433-4FE8-8707-CE73E7C292E5Q33806054-D951A08A-9794-426B-B2E8-6C9A3A906A3BQ33873523-578C4133-22AF-47F1-906E-A7B878D1C154Q33925257-754C98DE-28E2-4F88-B647-F4CA646B134FQ34055591-ECD34108-5B14-43AC-A6D6-BF488B38C16EQ34056677-65BF5D34-0AE4-458B-A9FB-591A6849D0ECQ34087018-E55A260F-39F8-45F3-826C-20C62F3678F9Q34111103-D9B88849-D375-49CF-ACFC-2CF9C3E55D4CQ34156000-4AA8219A-A816-42E9-B592-CFD31EAB886FQ34180301-35383EE9-F02D-45CA-AD76-C396B0951F4FQ34388640-9C6AF3B7-9E6D-47C5-A5CB-D5BFEE959E22Q34549151-0FCC4367-2D77-4851-AAE5-5EA3D7894B5AQ34549158-5449AF65-4832-45EF-B4CC-599986D9066EQ34698294-CD6E6B15-01A5-448F-A894-1A5BED51AB07Q35169948-61BD4381-22AE-4836-B0BE-975D76518870Q35623650-87901327-AED5-4F26-89AE-41BEC11B566AQ35765724-82048C3C-EBE8-4FB6-93AE-1A4BF0C0A796Q35914847-DA164408-466D-4720-8890-965FAA112C7DQ35986609-CB910FA1-CC9D-4A43-8DD4-AD5F7746803EQ36077893-C52644D8-7762-4016-A4E9-C4F85788D3B4Q36206430-47549746-A4D8-4A62-84A6-D1A8925A746CQ36384699-C9C4B460-DF9B-4401-B7A4-F4FBC2BC9F5EQ36503248-A5BB92F6-2EC1-416C-B13C-1E0B876DABF0Q36979082-808BD8FD-6E79-41A0-9D93-CE132069F542Q37098221-D82C6BE7-D7AA-4B14-9D04-B2DE039B956AQ37133709-F79D2374-E931-4514-BA52-12812DE4371DQ37152828-88BDE7D0-876D-481B-B071-05A1D7566A27Q37435436-858D85AC-D190-4265-8A72-30D9640DB6B9Q37524270-DDEF40F1-C1A7-4AF2-8CFF-0CAF0DE015F1Q37535244-D90CC3D9-CF45-40D4-A572-DD78398328FE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
William Matsui
@ast
William Matsui
@en
William Matsui
@es
William Matsui
@nl
William Matsui
@sl
type
label
William Matsui
@ast
William Matsui
@en
William Matsui
@es
William Matsui
@nl
William Matsui
@sl
prefLabel
William Matsui
@ast
William Matsui
@en
William Matsui
@es
William Matsui
@nl
William Matsui
@sl
P106
P1153
6602749378
P21
P31
P496
0000-0002-3088-0964